ENLV
Enlivex Therapeutics (ENLV)
$85
About Enlivex Therapeutics (ENLV)
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Details
Daily high
$0.88
Daily low
$0.79
Price at open
$0.87
52 Week High
$2.10
52 Week Low
$0.79
Market cap
20.9M
Dividend yield
0.00%
Volume
1.2M
Avg. volume
12.2M
P/E ratio
-1.61
Enlivex Therapeutics News
Details
Daily high
$0.88
Daily low
$0.79
Price at open
$0.87
52 Week High
$2.10
52 Week Low
$0.79
Market cap
20.9M
Dividend yield
0.00%
Volume
1.2M
Avg. volume
12.2M
P/E ratio
-1.61